Table 1 Patient characteristics at first local treatment
Parameter | Total cohort (N = 40) |
|---|---|
ESTRO/EORTC Type of oligometastatic disease, n (%) | |
Metachronous Oligorecurrence | 27 (68%) |
Synchronous Oligometastatic disease | 13 (33%) |
Age, years | |
Median (IQR) | 60.5 (56.3–70.8) |
Mean (range) | 62.0 (41.0–82.0) |
ECOG, n (%) | |
ECOG 0 | 5 (13%) |
ECOG 1 | 18 (45%) |
ECOG 2 | 14 (35%) |
ECOG 3 | 3 (8%) |
Histology, n (%) | |
Squamous cell carcinoma | 33 (83%) |
Lymphoepithelial carcinoma | 3 (8%) |
Adenocarcinoma | 2 (5%) |
Neuroendocrine carcinoma | 1 (3%) |
Undifferentiated | 1 (3%) |
Original site of Head and Neck primary, n (%) | |
Hypopharynx | 11 (28%) |
Larynx | 9 (23%) |
Oropharynx | 7 (18%) |
Head and neck cancer of unknown primary | 5 (13%) |
Nasal cavity/paranasal sinuses | 4 (10%) |
Oral cavity | 3 (8%) |
Nasopharynx | 1 (3%) |
Number of metastases | |
Median (IQR) | 1.0 (1.0–2.0) |
Mean (range) | 1.6 (1.0–7.0) |
Metastatically involved organ systems, n (%) | |
One organ system | 34 (85%) |
Two organ systems | 6 (15%) |
Metastatically involved organ sitesa, n (%) | |
Pulmonary | 23 (58%) |
Lymphonodal | 11 (28%) |
Bone | 6 (15%) |
Hepatic | 3 (8%) |
Brain | 2 (5%) |
Total tumor volume, cm3 | |
Median (IQR) | 19.7 (2.0-46.8) |
Mean (range) | 49.5 (0.2–550.8) |
Total metastases volume, cm3 | |
Median (IQR) | 9.4 (1.6–23.2) |
Mean (range) | 24.5 (0.2–240.6) |
Number of active tumor sites (metastases + primary) | |
Median (IQR) | 2.0 (1.0–2.0) |
Mean (range) | 1.8 (1.0–7.0) |
Locoregional tumor, n (%) | |
No | 28 (70%) |
Primary manifestation | 7 (18%) |
Recurrence | 5 (13%) |
Locoregional tumor site, n (%) | |
Primary and involved regional lymph nodes | 7 (18%) |
Regional lymph nodes only | 3 (8%) |
Primary only | 2 (5%) |
Total locoregional tumor volume, cm3 | |
Median (IQR) | 0.0 (0.0–7.0) |
Mean (range) | 24.9 (0.0–502.4) |
Previous head and neck radiotherapy, n (%) | |
Prior head and neck radiotherapy | 31 (78%) |
No prior head and neck radiotherapy | 9 (23%) |
Previous head and neck surgery, n (%) | |
Prior head and neck surgery | 23 (58%) |
No prior head and neck surgery | 17 (43%) |
Histologic proof of metastatic disease, n (%) | |
Yes | 22 (55%) |
No | 18 (45%) |
FDG-PET staging, n (%) | |
Yes | 13 (33%) |
No | 27 (68%) |
Interval from diagnosis of OMD to first local treatment, months | |
Median (IQR) | 1.3 (0.9–2.2) |
Mean (range) | 1.7 (0–7.3) |
Total duration of OMD first-line treatment, months | |
Median (IQR) | 3.1 (2.2–4.6) |
Mean (range) | 3.7 (0.3–10.8) |
Local treatment for OMDa, n (%) | |
Radiotherapy | 36 (90%) |
Surgery | 10 (25%) |
Interventional radiology | 1 (3%) |
Biologically effective dose (α/β = 10)b, Gy | |
Median (IQR) | 78.8 (67.2–111.4) |
Mean (range) | 82.6 (39.0–115.2) |
Systemic treatment, n (%) | |
Platinum-combination treatment | 14 (35%) |
Single-agent cytostatic chemotherapy alone | 4 (10%) |
Cetuximab alone | 4 (10%) |
Platinum-combination + Cetuximab | 2 (5%) |
Immune checkpoint inhibitor | 2 (5%) |
No concurrent systemic treatment | 14 (35%) |